Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
about
Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experienceTargeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinibNovel agents in the treatment of multiple myeloma: a review about the futureRole of the tumor microenvironment in mature B-cell lymphoid malignanciesIbrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaCD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasThe role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?IbrutinibNovel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyLymphoma Immunotherapy: Current StatusIbrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinionRecent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomasRole of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell NeoplasmsMyeloid Cells as Targets for Therapy in Solid TumorsPredictive biomarkers in precision medicine and drug development against lung cancerTargeting the B-cell receptor signaling pathway in B lymphoid malignanciesRisk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsRisk factors for etiology and prognosis of mantle cell lymphomaBruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomasBruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinibManagement of mantle cell lymphoma in the elderly patientHigh-dimensional single-cell cancer biologyTargeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibIbrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinaseNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewAACR Cancer Progress Report 2014Acalabrutinib (ACP-196): a selective second-generation BTK inhibitorPrevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapyMantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agentsSecond-generation inhibitors of Bruton tyrosine kinaseManagement of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitorsSecondary mutations as mediators of resistance to targeted therapy in leukemiaTargets for Ibrutinib Beyond B Cell MalignanciesMantle cell lymphoma: observation to transplantationDetailed Functional and Proteomic Characterization of Fludarabine Resistance in Mantle Cell Lymphoma CellsThe European Hematology Association Roadmap for European Hematology Research: a consensus documentLong-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.Bcl-2high mantle cell lymphoma cells are sensitized to acadesine with ABT-199.Pseudokinases: update on their functions and evaluation as new drug targets.
P2860
Q26738946-49371A64-DB7B-41B3-8CAA-62D7D0BEC922Q26744277-B34FA44F-3EBF-4F81-A882-DD089D9468F8Q26745924-1C1C89D4-927E-4D23-A7B1-E1E22BAD0F47Q26748775-46CDDC29-337D-4D81-AF0F-D7025DDFF12DQ26749010-4D2FE350-7FF3-4109-A930-16AFB2B04118Q26749139-A8A14F9C-C64F-45FA-8BF7-2FA574DF7837Q26772907-73EC22B4-DE07-491F-804A-9243FFB7A61FQ26773236-46D228D5-F55D-468C-8F7D-535F762357D3Q26782270-A6ED571D-3E4A-48BE-9EC4-F6B00D02B661Q26782902-09E74A49-7645-4DD0-8213-3BBDDC639CE4Q26783430-71397375-4775-41B8-ADE4-CFAF039FFD29Q26784108-2FBB14F9-6766-46E4-907C-764D1AA53BA6Q26795594-6606A02C-4619-48CD-8441-A19369351075Q26801832-E1B7DF38-85E6-4A68-893B-008F10191C26Q26824536-41500F60-D7AD-4CE6-BB84-33FAF424CD14Q26828782-D1AE147A-E171-4321-BD45-356421481FC3Q26851417-91DAA877-D102-4763-A822-55CEF80238C1Q26858960-949EAF05-70EB-4175-84A8-0E2FCBF6AA1BQ26991890-0BEE84ED-584D-4E78-B1C8-810E0843F19CQ26995113-1B68BEED-2DF1-41D1-AB9A-24D3AD47334DQ26999395-5C5CDC15-25CB-4168-8647-1DEB19894893Q27021173-8567B872-D0A8-4FF5-9514-B740EA5D4703Q27025812-E9F40E11-852C-498F-B196-F22EB72455F8Q27026912-9D0BB901-0662-4F5B-9348-B3F9A7823C42Q27304386-C1A454A6-8270-4B93-A59C-981817F9C25AQ27346723-6CA50BCE-B2C4-4EDB-9AD1-1F684C5ABFD5Q28066316-0B37A9EF-FD92-45F6-9117-009695AF8566Q28070090-399647BB-5216-4512-9750-BD0AEE583254Q28075606-DF84403E-FEEF-432C-8B30-CA67D696664BQ28076118-49470A99-A347-4895-AB10-B6BA306F5DAAQ28081162-FABA0947-24A1-4908-86CD-3F30132443B0Q28087213-ED4F1C7D-872E-47DC-88BF-5E1A47303877Q28087772-0572365E-9F5C-4682-8FDE-8AD8DF8FBCDDQ28256317-D1B8D570-8709-4408-98C4-9C2FE0D3A8DDQ28547322-19180852-74F8-43A9-AE5A-FA321AB0E110Q28830861-21740798-9ECE-46A6-815F-97CDE28B5F10Q30279207-9CE46656-110C-4F9C-9533-2DC5455F506FQ30303054-9822B65B-9CF0-403B-943D-95D9952711E5Q30395557-ED7E248A-E3B3-4DE5-ABD1-76C1B32605F0Q30397636-DABB6BDE-9CBC-4014-A6BE-28E8460BD10E
P2860
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
@ast
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
@en
type
label
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
@ast
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
@en
prefLabel
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
@ast
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
@en
P2093
P2860
P50
P356
P1476
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
@en
P2093
Betty Y Chang
Bingliang Fang
Brad S Kahl
Darrin M Beaupre
Ewa Chmielowska
Jesse McGreivy
Jorge E Romaguera
Joseph J Buggy
P2860
P304
P356
10.1056/NEJMOA1306220
P407
P577
2013-06-19T00:00:00Z